This study showed the anti‐inflammatory effects of interferon lambda 1‐expressing probiotics in two in‐vitro IBD models, demonstrating their potential as live biotherapeutics for IBD immunotherapy. This evidence concerns the gene IFNL1 and irritable bowel syndrome.